ZYG11B

Across TCGA pan-cancer cohorts, ZYG11B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZYG11B data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher ZYG11B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZYG11B expression acts as an unfavorable survival marker.

PRAD, ACC, and SCLC are the cancer types where ZYG11B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZYG11B–PRAD (DFS)

Open the PRAD breakdown →